Clinical Trial Detail

NCT ID NCT01683188
Title HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Prometheus Laboratories
Indications

melanoma

Therapies

Aldesleukin + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST